Britain and America have finalized a significant trade agreement that will preserve no levies on British medicine exports being sold in the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to boost funding on pharmaceuticals through the National Health Service (NHS). This move ensures that tariffs on these vital goods will be held at nothing for a period of the next three years.
This agreement follows previous threats to dramatically increase import taxes on patented drug imports, with potential rates mentioned up to double the cost.
"This arrangement with the UK reinforces the global environment for new treatments and brings much-needed equity to U.S.–U.K. pharmaceutical trade," a statement noted.
Commercial Importance
Pharmaceuticals are one of the Britain's most significant exports to the United States, which is clearly the biggest market for large British pharmaceutical firms.
Export figures show that in the year leading up to last September, the UK exported drugs valued at billions to the US. This figure accounted for nearly one-fifth of all goods exports in that timeframe.
"This guarantee safeguards jobs, increases capital expenditure and sets the stage for the UK to emerge as a international leader for life sciences," a government official commented.
Key British Pledges
The deal involves several key changes from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to double overall public funding on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must return to the NHS to stay within budget will be capped at 15%. Previously, refunds topped twenty percent.
Recent Tensions
The pact comes amid a long-running dispute between the pharmaceutical industry and the UK government over drug pricing and approval rates.
The disagreement were exacerbated by claims that American patients were charged several times more for the identical medicines than patients in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been pledged toward projects in the United States.
One official acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had shrunk as a proportion of its resources over the last ten years.
